FDA Rejection Of Narrowed Indication For Daxas Led To Negative Panel Vote
Executive Summary
If FDA had accepted Forest's proposed revised indication for Daxas (roflumilast), the chronic obstructive pulmonary disease drug could have yielded a different outcome from the Pulmonary-Allergy Drugs Advisory Committee
You may also be interested in...
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Forest Laboratories and Spain's Almirall report positive late-stage data for their COPD drug, paving the way for 2011 regulatory filings in the U.S. and EU.
Positive COPD Data Allows Forest To File For Approval of Eklira in 2011
Forest Laboratories and Spain's Almirall report positive late-stage data for their COPD drug, paving the way for 2011 regulatory filings in the U.S. and EU.